Abstract
Retinal thickness is a marker of retinal health and more broadly, is seen as a promising biomarker for many systemic diseases. Retinal thickness measurements are procured from optical coherence tomography (OCT) as part of routine clinical eyecare. We processed the UK Biobank OCT images using a convolutional neural network to produce fine-scale retinal thickness measurements across >29,000 points in the macula, the part of the retina responsible for human central vision. The macula is disproportionately affected by high disease burden retinal disorders such as age-related macular degeneration and diabetic retinopathy, which both involve metabolic dysregulation. Analysis of common genomic variants, metabolomic, blood and immune biomarkers, ICD10 codes and polygenic risk scores across a fine-scale macular thickness grid, reveals multiple novel genetic loci-including four on the X chromosome; retinal thinning associated with many systemic disorders including multiple sclerosis; and multiple associations to correlated metabolites that cluster spatially in the retina. We highlight parafoveal thickness to be particularly susceptible to systemic insults. These results demonstrate the gains in discovery power and resolution achievable with AI-leveraged analysis. Results are accessible using a bespoke web interface that gives full control to pursue findings.
Competing Interest Statement
A.Y.L. reports grants from Santen, personal fees from Genentech, personal fees from US FDA, personal fees from Johnson and Johnson, personal fees from Boehringer Ingelheim, non-financial support from iCareWorld, grants from Topcon, grants from Carl Zeiss Meditec, personal fees from Gyroscope, non-financial support from Optomed, non-financial support from Heidelberg, non-financial support from Microsoft, grants from Regeneron, grants from Amazon, grants from Meta, outside the submitted work; This article does not reflect the views of the US FDA. A.T. reports no direct funding conflicts with the content of the paper. Other disclosures not directly related to the content of the paper: Allergan; Annexon; Apellis; Bayer; 4DMT; Genetech; Heidelberg Engineering; Iveric Bio; Novartis; Oxurion; Roche; VisionAI. C.Y.E. reports receiving financial support from the UK Department of Health through an award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology. C.Y.E. receives consultant fees from Heidelberg Engineering and Inozyme Pharma unrelated to the scope of the current work. No competing interests reported for M.B., J.O., M.L.G., R.B., B.R.E.A., K.W., V.E.J., S.F.,Y.K.,Y.W..
Funding Statement
This work was supported by funding from the Australian Government National Health and Medical Research Council (NHMRC) from APP1195236 (M.B.) and APP1181010(B.R.E.A.). This work was also made possible through the Victorian State Government Operational Infrastructure Support and NHMRC Independent Research Institute Infrastructure Support Scheme (IRIISS). We also thank the Lowy Medical Research Institute (LMRI) for laboratory support to A.Y.L. and M.B. and institutional support to C.Y.E.. C.Y.E. and A.T.l received a proportion of their financial support from the UK Department of Health through an award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology. A.T. and C.Y.E. acknowledge financial support from the Said Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research was approved by the Walter and Eliza Hall Institute of Medical Research Human Ethics Committee (HREC 17/09LR). This study used data from the UK Biobank (application 28541). UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. This approval means that researchers do not require separate ethical clearance and can operate under the RTB approval. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵^ = joint last authors
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.